Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769857 | 0.92 | OPRK1 (0.56) | OPRK1SIGMAR1ADRB2LMNASLC6A2 | |
| SCHEMBL18769856 | 0.86 | SIGMAR1 (0.68) | OPRK1SIGMAR1ADRB2LMNASLC6A2 | |
| SCHEMBL18769851 | 0.79 | SIGMAR1 (0.46) | OPRK1SIGMAR1ADRB2SLC6A2SLC6A4 | |
| SCHEMBL19505657 | 0.75 | SIGMAR1 (0.83) | OPRK1SIGMAR1MEN1KMT2ASLC2A1 | |
| SCHEMBL19505613 | 0.75 | SIGMAR1 (0.83) | OPRK1SIGMAR1MEN1KMT2ASLC2A1 | |
| SCHEMBL18769895 | 0.72 | ADRB2 (0.58) | OPRK1SIGMAR1ADRB2KDM4EMAPK1 | |
| SCHEMBL31734116 | 0.72 | OPRK1 (1.00) | OPRK1SIGMAR1ADRB2LMNASLC6A2 | |
| SCHEMBL18769831 | 0.71 | ADRB2 (0.58) | ADRB2SLC6A2SLC6A4OPRM1HIF1A | |
| SCHEMBL18792143 | 0.70 | ADRB2 (0.39) | SIGMAR1ADRB2HIF1AMAPK1CYP2D6 | |
| SCHEMBL31734098 | 0.69 | OPRK1 (0.68) | OPRK1SIGMAR1ADRB2LMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | claimed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | claimed |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | BRCA1, VHL, TP53 | OPRK1 3511/4885SIGMAR1 4450/4885ADRB2 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.